168 related articles for article (PubMed ID: 35472093)
1. Incidence of anogenital warts after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada.
Righolt CH; Willows K; Kliewer EV; Mahmud SM
PLoS One; 2022; 17(4):e0267646. PubMed ID: 35472093
[TBL] [Abstract][Full Text] [Related]
2. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
Nygård S; Nygård M; Orumaa M; Hansen BT
Vaccine; 2023 Aug; 41(37):5469-5476. PubMed ID: 37516572
[TBL] [Abstract][Full Text] [Related]
3. Early Evidence of the Effectiveness of the Human Papillomavirus Vaccination Program Against Anogenital Warts in Manitoba, Canada: A Registry Cohort Study.
Willows K; Bozat-Emre S; Righolt CH; Kliewer EV; Mahmud SM
Sex Transm Dis; 2018 Apr; 45(4):254-259. PubMed ID: 29465699
[TBL] [Abstract][Full Text] [Related]
4. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment.
Guerra FM; Rosella LC; Dunn S; Wilson SE; Chen C; Deeks SL
Vaccine; 2016 Sep; 34(39):4678-4683. PubMed ID: 27527815
[TBL] [Abstract][Full Text] [Related]
5. The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada.
Steben M; Ouhoummane N; Rodier C; Sinyavskaya L; Brassard P
J Med Virol; 2018 Mar; 90(3):592-598. PubMed ID: 28980715
[TBL] [Abstract][Full Text] [Related]
6. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts.
Smith LM; Strumpf EC; Kaufman JS; Lofters A; Schwandt M; Lévesque LE
Pediatrics; 2015 May; 135(5):e1131-40. PubMed ID: 25917991
[TBL] [Abstract][Full Text] [Related]
7. A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada.
Steben M; Tan Thompson M; Rodier C; Mallette N; Racovitan V; DeAngelis F; Stutz M; Rampakakis E
J Obstet Gynaecol Can; 2018 Dec; 40(12):1635-1645. PubMed ID: 30341021
[TBL] [Abstract][Full Text] [Related]
8. Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017.
Checchi M; Mesher D; Mohammed H; Soldan K
Sex Transm Infect; 2019 Aug; 95(5):368-373. PubMed ID: 30723186
[TBL] [Abstract][Full Text] [Related]
9. Health service utilisation for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine programme introduction: a retrospective longitudinal population-based study.
Guerra FM; Rosella LC; Dunn S; Wilson SE; Chen C; Deeks SL
BMJ Open; 2016 Mar; 6(3):e009914. PubMed ID: 26966057
[TBL] [Abstract][Full Text] [Related]
10. Increasing incidence of anogenital warts with an urban-rural divide among males in Manitoba, Canada, 1990-2011.
Thompson LH; Nugent Z; Blanchard JF; Ens C; Yu BN
BMC Public Health; 2016 Mar; 16():219. PubMed ID: 26939696
[TBL] [Abstract][Full Text] [Related]
11. The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity.
Orumaa M; Kjaer SK; Dehlendorff C; Munk C; Olsen AO; Hansen BT; Campbell S; Nygård M
Vaccine; 2020 Feb; 38(6):1345-1351. PubMed ID: 31917039
[TBL] [Abstract][Full Text] [Related]
12. Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women.
Brotons M; Monfil L; Roura E; Duarte-Salles T; Casabona J; Urbiztondo L; Cabezas C; Bosch FX; de Sanjosé S; Bruni L
Prev Med; 2020 Sep; 138():106166. PubMed ID: 32565118
[TBL] [Abstract][Full Text] [Related]
13. Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination.
Naleway AL; Crane B; Smith N; Francisco M; Weinmann S; Markowitz LE
Sex Transm Dis; 2020 Mar; 47(3):179-186. PubMed ID: 31880738
[TBL] [Abstract][Full Text] [Related]
14. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women--an ecological study.
Sandø N; Kofoed K; Zachariae C; Fouchard J
Acta Derm Venereol; 2014 May; 94(3):288-92. PubMed ID: 24150529
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
Dominiak-Felden G; Gobbo C; Simondon F
PLoS One; 2015; 10(7):e0132404. PubMed ID: 26147096
[TBL] [Abstract][Full Text] [Related]
16. Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination.
Tyros G; Mastraftsi S; Gregoriou S; Nicolaidou E
Int J STD AIDS; 2021 Jan; 32(1):4-13. PubMed ID: 33167803
[TBL] [Abstract][Full Text] [Related]
17. Impacts of Human Papillomavirus Immunization Programs on Rates of Anogenital Warts in British Columbia, Canada, 2000 to 2017.
Lukac CD; Donken R; Otterstatter M; Mazo O; Wong S; Marra F; Smith L; Naus M; Money D; Krajden M; Grennan T; Gilbert M; Wong J; Ogilvie GS
Sex Transm Dis; 2020 Oct; 47(10):691-697. PubMed ID: 32649583
[TBL] [Abstract][Full Text] [Related]
18. Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients.
Woestenberg PJ; Guevara Morel AE; Bogaards JA; Hooiveld M; Schurink-van 't Klooster TM; Hoebe CJPA; van der Sande MAB; van Benthem BHB
Clin Infect Dis; 2021 Jul; 73(2):291-297. PubMed ID: 32421775
[TBL] [Abstract][Full Text] [Related]
19. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study.
Lamb F; Herweijer E; Ploner A; Uhnoo I; Sundström K; Sparén P; Arnheim-Dahlström L
BMJ Open; 2017 Jun; 7(6):e015021. PubMed ID: 28600369
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of school-based and high-risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada.
Righolt CH; Bozat-Emre S; Mahmud SM
Int J Cancer; 2019 Aug; 145(3):671-677. PubMed ID: 30653261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
